Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-25T19:48:08.379Z Has data issue: false hasContentIssue false
  • English
  • Français

Update on Alzheimer's Disease: One Hundred Years After Dr. Alois Alzheimer

Published online by Cambridge University Press:  07 November 2014

Jeffrey L. Cummings
Get access Rights & Permissions [Opens in a new window]

Extract

Alzheimer's disease was first described by Alois Alzheimer in 1906, and first appeared in the medical literature in 1907. The medical community has been ruminating about Alzheimer's disease for over 100 years, and only recently have Alzheimer's disease therapies begun to emerge. However, many vital questions remain, pertinent not only to physicians but to the public at large. For example, how likely is it that a particular individual will develop Alzheimer's disease? What can one do to avoid getting Alzheimer's disease? What are the current and promising treatments for Alzheimer's disease? While there are grey areas, the Alzheimer's disease field is beginning to find solid answers to these questions. There are risk factors that individuals can control, and emerging treatments are cause for optimism.

Type
Expert Roundtable Supplement
Information
CNS Spectrums , Volume 13 , Issue S2: Creativity and Dementia: Emerging Diagnostic and Treatment Methods for Alzheimer's Disease , February 2008 , pp. 4 - 6
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Alzheimer, A.Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift für Psychiatrie und Psychisch-Gerichtliche Medizin. 1907;64:146–148.Google Scholar
2.Jorm, AF, Korten, AE, Henderson, AS.The prevalence of dementia: a quantitative integration of the literature. Neurology. 1987;43:465–479.Google Scholar
3.Corder, EH, Saunders, AM, Strittmatter, WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease. Science. 1993;261(5123):921–923.CrossRefGoogle ScholarPubMed
4.Arvanitakis, Z, Wilson, RS, Bienias, JL, Evans, DA, Bennett, DA.Diabetes Mellitus and risk of Alzheimer's disease and decline in cognitive function. Arch Neurol. 2004;61(5):661–666.CrossRefGoogle ScholarPubMed
5.Luchsinger, JA, Tang, MX, Shea, S, Mayeux, R.Hyperinsulinemia and rish of Alzheimer disease. Neurology. 2004;63(7):1187–1192.CrossRefGoogle Scholar
6.Launer, LJ, Ross, GW, Petrovitch, H, et al. Midlife blood pressure and dementia: the Honolulu-Asia Aging Study. Neurobiol Aging. 2000;21(1):49–55.CrossRefGoogle ScholarPubMed
7.Verghese, J, Lipton, RB, Hall, CB, Kuslansky, G, Katz, MJ.Low blood pressure and the risk of dementia in very old individuals. Neurology. 2003;61(12):1667–1672.CrossRefGoogle ScholarPubMed
8.Qiu, C, von Strauss, E, Fastbom, J, Winblad, B, Fratiglioni, L.Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arch Neurol. 2003;60(2):223–228.CrossRefGoogle Scholar
9.Van Osch, LA, Hogervorst, E, Combrinck, M, Smith, AD.Low thyroid-stimulating hormone as an independent risk factor for Alzheimer disease. Neurology. 2004;62(11):1967–1971.CrossRefGoogle ScholarPubMed
10.Ott, A, Andersen, K, Dewey, ME, et al. Effect of smoking on global cognitive function in nondemented elderly. Neurology. 2004;62(6):920–924.CrossRefGoogle ScholarPubMed
11.Honig, LS, Tang, MX, Albert, S, et al. Stroke and the risk of Alzheimer disease. Arch Neurology. 2003;60(12):1707–1712.CrossRefGoogle ScholarPubMed
12.Graves, AB, Mortimer, JA, Bowen, JD, et al. Head circumference and incident Alzheimer's disease. Neurology. 2001;57:1453–1460.CrossRefGoogle Scholar
13.McIlroy, SP, Dynan, KB, Lawson, JT, Patterson, CC, Passmore, AP.Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke. 2002;33(10):2351–2356.CrossRefGoogle ScholarPubMed
14.Pappolla, MA, Bryant-Thomas, TK, Herbert, D, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer and amyloid pathology. Neurology. 2003;61(2):199–205.CrossRefGoogle ScholarPubMed
15.Orgogozo, JM, Dartigues, JF, Lafont, S, et al. Wine consumption and dementia in the elderly: A prospective community study in the Bordeaux area. Rev Neurol (Paris). 1997;153(3):185–192.Google ScholarPubMed
16.Lytle, ME, Vander, Bilt J, Pandav, RS, Dodge, HH, Ganguli, M.Exercise level and cognitive decline: the MoVIES project. Alzheimer Dis Assoc Disord. 2004;18(2):57–64.CrossRefGoogle ScholarPubMed
17.Small, GW, Kepe, V, Ercoli, LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355(25):2652–2663.CrossRefGoogle ScholarPubMed
18.Klunk, WE, Engler, H, Nordberg, A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–319.CrossRefGoogle ScholarPubMed
19.Garcia-Alloza, M, Borrelli, LA, Rozkalne, A, Hyman, BT, Bacskai, BJ.Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem. 2007;102(4):1095–1104.CrossRefGoogle Scholar